Global AI based Clinical Trial Solution Provider Market
Share With :
Artificial Intelligence is set of smart technologies that develop and learn from data and perform tasks based on previous experience. The process, clinical trials are a very crucial that enable both innovators and regulators to assess the efficacy of a candidate drug, use of AI in clinical trial save the time and cost efficiencies by providing faster insights to form the decision. AI helps Investigator to answer some questions inlcuding how to consuct study design, site identification & patient recruitment for clinical research and to digitize adverse drug reaction (ADR) documents in pharmacovigilance. The successfully developing a novel therapeutic intervention required around 10 years of time and cost around USD 2.5 billion, However, use of technology like artificial intelligent in clinical trial help to save huge amount of money as well as time.
Increasing number of strategic alliances in deployment of Artificial Intelligence (AI) in clinical trials aims to reduce time as well expenditure during clinical developmental phases is expected to create the lucrative growth in market near the future. Additionally, Regulators around the world have released guideline that encourage biopharma companies to use real world evidence strategies. For instance, US FDA has passed the 21st Century Cures Act, in 2016, that was designed to help bring new innovations and advances to patients more efficiently and faster.
The Global AI-Based Clinical Trial Solution Provider market is segmented on the basis of target therapeutic area, trial phase, end users and region. Based on the therapeutic area, the market is divided into cardiovascular disorders, cns disorders, infectious disorders, metabolic disorders, oncological disorders and other disorders. Based on the trial phase, the market is divided into early phase 1, phase 1, phase 2, phase 3 and phase 4. Based on the end users, the market is divided into pharmaceutical companies, academia and other users. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
The key players of this market include Antidote Technologies, Inc., AiCure, LLC, Deep 6 AI, Deep Lens Inc., Innoplexus, Intelligencia.ai, MEDIAN Technologies, Mendel.ai, Phesi, Saama Technologies, Unlearn.AI, Inc. and Trials.ai
Artificial Intelligence is set of smart technologies that develop and learn from data and perform tasks based on previous experience. The process, clinical trials are a very crucial that enable both innovators and regulators to assess the efficacy of a candidate drug, use of AI in clinical trial save the time and cost efficiencies by providing faster insights to form the decision. AI helps Investigator to answer some questions inlcuding how to consuct study design, site identification & patient recruitment for clinical research and to digitize adverse drug reaction (ADR) documents in pharmacovigilance. The successfully developing a novel therapeutic intervention required around 10 years of time and cost around USD 2.5 billion, However, use of technology like artificial intelligent in clinical trial help to save huge amount of money as well as time.
Increasing number of strategic alliances in deployment of Artificial Intelligence (AI) in clinical trials aims to reduce time as well expenditure during clinical developmental phases is expected to create the lucrative growth in market near the future. Additionally, Regulators around the world have released guideline that encourage biopharma companies to use real world evidence strategies. For instance, US FDA has passed the 21st Century Cures Act, in 2016, that was designed to help bring new innovations and advances to patients more efficiently and faster.
The Global AI-Based Clinical Trial Solution Provider market is segmented on the basis of target therapeutic area, trial phase, end users and region. Based on the therapeutic area, the market is divided into cardiovascular disorders, cns disorders, infectious disorders, metabolic disorders, oncological disorders and other disorders. Based on the trial phase, the market is divided into early phase 1, phase 1, phase 2, phase 3 and phase 4. Based on the end users, the market is divided into pharmaceutical companies, academia and other users. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
The key players of this market include Antidote Technologies, Inc., AiCure, LLC, Deep 6 AI, Deep Lens Inc., Innoplexus, Intelligencia.ai, MEDIAN Technologies, Mendel.ai, Phesi, Saama Technologies, Unlearn.AI, Inc. and Trials.ai
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.